GenSci120

DRUG2 trials

Sponsors

Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions

Autoimmune DiseaseRheumatoid Arthritis

Phase 1

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

CompletedNCT06827457

Changchun GeneScience Pharmaceutical Co., Ltd.Autoimmune Disease

Start: 2025-02-20End: 2025-12-16Updated: 2025-12-24

Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.

RecruitingNCT07040930

Changchun GeneScience Pharmaceutical Co., Ltd.Rheumatoid Arthritis

Start: 2025-08-01End: 2026-09-20Target: 30Updated: 2025-08-06